CanSino Biologics Inc. (6185.HK)
HKSE · HKD · Healthcare · Drug Manufacturers - Specialty & Generic
HK$27.52 (-5.10%) as of
Key statistics
- Market cap
- 6.80B
- P/E (TTM)
- 152.89
- Forward P/E
- 15.40
- EPS (TTM)
- 0.180
- Dividend yield
- 0.00%
- 52-week range
- 19.220 – 47.800
- Beta
- 1.13
- Revenue (TTM)
- 1.24B
- Profit margin
- 3.29%
- Analyst target
- HK$47.57
- Volume
- 2.42M
About CanSino Biologics Inc.
CanSino Biologics Inc. develops, manufactures, and commercializes vaccines in the People's Republic of China. The company develops Ad5-nCoV for Inhalation vaccines to recombinant novel coronavirus disease; Ad5-EBOV, an Ebola virus vaccine; and MCV2 and MCV4 vaccines for the prevention of N. meningitides. It develops DTcP vaccine for infants and DTcP Booster vaccine, which are in Phase I clinical trial for addressing the weaker protection preventing pertussis after primary vaccination. In addition, it develops Tdcp Adolescent and Adult vaccine for treating pertussis; PBPV, a serotype-independent protein-based pneumococcal vaccine that is in Phase I clinical trial; PCV13i, a pneumococcal conjugate vaccine, which is in Phase I clinical trial; and TB Booster for the BCG-vaccinated population which is in Phase I clinical trial. Further, it is developing various preclinical stage products, including DTcP-Hib Combo vaccine; and CS-2023 to treat meningitis. The company was incorporated in 2009 and is headquartered in Tianjin, the People's Republic of China.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Headquarters
- Tianjin, China
- Employees
- 1,175
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.